Page last updated: 2024-10-22

tyrphostin ag 1024 and Cancer of Liver

tyrphostin ag 1024 has been researched along with Cancer of Liver in 1 studies

tyrphostin AG 1024: modulates radiosensitivity in human breast cancer cells; also an IGF1 receptor inhibitor

Research Excerpts

ExcerptRelevanceReference
"In contrast, p53 mutated Huh-7 hepatocellular cancer cells proved to be less sensitive towards cetuximab, but when combined with TKIs or fluvastatin or doxorubicin a pronounced reduction of cell growth was observed."1.33EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. ( Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2005)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Huether, A1
Höpfner, M1
Baradari, V1
Schuppan, D1
Scherübl, H1

Other Studies

1 other study available for tyrphostin ag 1024 and Cancer of Liver

ArticleYear
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
    Biochemical pharmacology, 2005, Nov-25, Volume: 70, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Cy

2005